"Using artificial intelligence technology, we can design and synthesize proteins that do not exist in nature. Generative AI is now the core technology for next-generation protein design."
A Nobel Prize-winning scholar who laid the foundation for "nanomedicine" through AI-powered protein design technology predicted that "generative AI will fundamentally transform the structure of entire industries — from next-generation infectious disease treatment and new drug development to chemical processes and recycling." The assessment is that the convergence of biomedical engineering and AI technology has opened an era in which nanometer-scale (one-billionth of a meter) proteins can be precisely designed to perform desired functions.
On Tuesday, David Baker, a professor at the University of Washington, made these remarks during a keynote speech at the "Yonsei-IBS Nobel Forum," jointly hosted by the Yonsei Institute for Advanced Science (YIAS) and the Institute for Basic Science (IBS) Center for Nanomedicine. This marks Baker's first visit to South Korea since winning the 2024 Nobel Prize in Chemistry.
